Real World Evidence Study With Restrictive Diet and Otral Nutritional Supplementation on Pediatric Patients With Active Chron Disease

Prior treatment

• Patients who, in the investigator's opinion, will require surgical treatment or initiation of steroids or biological drugs (anti-TNF, vedolizumab or ustekinumab) within the next 3 months and for whom nutritional support is indicated exclusively as a bridge. Patients who are undergoing biological treatment but discontinue treatment due to non-response and initiate CDED+NEP are not excluded.

Other illness

• Patients with ulcerative colitis and/or unclassified inflammatory bowel disease.
• Patients with more than 36 months of disease progression.
• Active perianal disease.

Other

• Penetrating (B3) and/or non-inflammatory stenosing (B2) pattern.
• Presence of extraintestinal manifestations.

• Patients with Crohn's disease (diagnosis based on clinical, laboratory, endoscopic, radiological, and histological criteria, according to the revised Porto criteria of the ESPGHAN for the diagnosis of inflammatory bowel disease in children and adolescents);
• Aged between 8 and 18 years;
• Who are about to start treatment with NEP + CDED, i.e. CDED-naive patients who may have previously received treatment with NEE;
• With active Crohn's disease defined by the Weighted Paediatric Crohn's Disease Activity Index (wPCDAI) ≥ 12.5;
• With data collection available for the following 6 months;
• Able to follow the study protocol or whose parent/caregiver is able to adhere to the study protocol, according to the investigator's perspective.